Nichol G M, Nix A, Chung K F, Barnes P J
Department of Thoracic Medicine, National Heart and Lung Institute, Brompton Hospital, London.
Thorax. 1989 Dec;44(12):1009-14. doi: 10.1136/thx.44.12.1009.
Inhalation of sodium metabisulphite is thought to induce bronchoconstriction by release of sulphur dioxide. We sought to establish the reproducibility of the airway response to inhaled sodium metabisulphite given in increasing doubling concentrations (0.3 to 160 mg/ml) to 13 asthmatic and five atopic non-asthmatic subjects and the contribution of cholinergic mechanisms to this response. In 15 of the 18 subjects bronchoconstriction was sufficient to allow calculation of the dose of metabisulphite causing a 20% reduction in the forced expiratory volume in one second (FEV1) from baseline values (PD20 metabisulphite). The 95% confidence limit for the difference between this and a second PD20 metabisulphite determined 2-14 days later was 2.5 doubling doses. The difference between repeat PD20 metabisulphite measurements was unrelated to the number of days between challenges or change in baseline FEV1. Ten subjects returned for a third study 3-120 days after the second challenge; variability in PD20 metabisulphite did not differ from that seen between the first and second challenges. PD20 methacholine was determined between the two metabisulphite challenges and found to correlate with PD20 metabisulphite (r = 0.71). Inhaled ipratropium bromide 200 micrograms given in a randomised, placebo controlled, crossover study to 10 subjects increased PD20 methacholine 42 fold but had no significant effect on the response to metabisulphite. A single inhalation of the PD20 metabisulphite in five subjects induced maximal bronchoconstriction 2-3 minutes after inhalation, with a plateau in FEV1 lasting a further four minutes before recovery. A further single inhalation of the same PD20 dose 43 minutes later produced a 27% (SEM 4%) smaller fall in FEV1 than the first inhalation. These results show that metabisulphite PD20 values measured over days and weeks show similar reproducibility to those reported for histamine inhalation and that PD20 metabisulphite correlates with methacholine responsiveness. Most of the bronchoconstriction is not inhibited by antimuscarinic agents; the underlying mechanisms require further investigation.
吸入焦亚硫酸钠被认为会通过释放二氧化硫诱发支气管收缩。我们试图确定在13名哮喘患者和5名特应性非哮喘受试者中,以成倍增加的浓度(0.3至160毫克/毫升)吸入焦亚硫酸钠时气道反应的可重复性,以及胆碱能机制对该反应的作用。在18名受试者中的15名中,支气管收缩足以计算出使一秒用力呼气量(FEV1)较基线值降低20%的焦亚硫酸钠剂量(PD20焦亚硫酸钠)。在2至14天后测定的该剂量与第二次PD20焦亚硫酸钠之间差异的95%置信区间为2.5个成倍剂量。重复测量的PD20焦亚硫酸钠之间的差异与两次激发之间的天数或基线FEV1的变化无关。10名受试者在第二次激发后3至120天返回进行第三次研究;PD20焦亚硫酸钠的变异性与第一次和第二次激发之间观察到的情况没有差异。在两次焦亚硫酸钠激发之间测定了PD20乙酰甲胆碱,发现其与PD20焦亚硫酸钠相关(r = 0.71)。在一项随机、安慰剂对照、交叉研究中,给10名受试者吸入200微克异丙托溴铵,使PD20乙酰甲胆碱增加了42倍,但对焦亚硫酸钠反应没有显著影响。在5名受试者中单次吸入PD20焦亚硫酸钠在吸入后2至3分钟诱发最大支气管收缩,FEV1达到平台期并在恢复前再持续4分钟。43分钟后再次单次吸入相同PD20剂量导致FEV1下降幅度比第一次吸入小27%(标准误4%)。这些结果表明,数天和数周内测量的焦亚硫酸钠PD20值与吸入组胺报告的结果具有相似的可重复性,并且PD20焦亚硫酸钠与乙酰甲胆碱反应性相关。大多数支气管收缩不受抗毒蕈碱药物抑制;其潜在机制需要进一步研究。